Up a level |
Escriu, Carles ORCID: 0000-0003-3638-3202 and Field, John K ORCID: 0000-0003-3951-6365
(2016)
Circulating tumour DNA and resistance mechanisms during EGFR inhibitor therapy in lung cancer.
JOURNAL OF THORACIC DISEASE, 8 (9).
pp. 2357-2359.
Anpalakhan, Shobana, Huddar, Prerana, Behrouzi, Roya, Signori, Alessio, Cave, Judith, Comins, Charles, Cortellini, Alessio, Addeo, Alfredo, Escriu, Carles ORCID: 0000-0003-3638-3202, McKenzie, Hayley et al (show 7 more authors)
(2023)
The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 24 (2).
1746-.
Banna, Giuseppe L, Cantale, Ornella, Muthuramalingam, Sethupathi, Cave, Judith, Comins, Charles, Cortellini, Alessio, Addeo, Alfredo, Signori, Alessio, McKenzie, Hayley, Escriu, Carles ORCID: 0000-0003-3638-3202 et al (show 7 more authors)
(2022)
Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study.
INTERNATIONAL IMMUNOPHARMACOLOGY, 110.
108985-.
Piddock, Katherine, Nautiyal, Hritik, Ahmed, Mohammed, Barron, Melanie, Bhalla, Neeraj, Cook, Tim, Cubbin, Sarah, Davis, Gershan, Dobson, Rebecca, Escriu, Carles et al (show 10 more authors)
(2022)
Frailty, comorbidity and cardiovascular risk assessment in older patients with lung cancer.
.
Gillespie, Conor S, Mustafa, Mohammad A, Richardson, George E, Alam, Ali M ORCID: 0000-0001-6014-3263, Lee, Keng Siang, Hughes, David M ORCID: 0000-0002-1287-9994, Escriu, Carles ORCID: 0000-0003-3638-3202 and Zakaria, Rasheed ORCID: 0000-0001-6826-2662
(2023)
Genomic alterations and the incidence of brain metastases in advanced and metastatic non-small cell lung cancer: a systematic review and meta-analysis.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 18 (12).
S1556-0864(23)00638-X-S1556-0864(23)00638-X.
Anpalakhan, Shobana, Huddar, Prerana, Behrouzi, Roya, Signori, Alessio, Cave, Judith, Comins, Charles, Cortellini, Alessio, Addeo, Alfredo, Escriu, Carles ORCID: 0000-0003-3638-3202, McKenzie, Hayley et al (show 9 more authors)
(2023)
Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis.
FRONTIERS IN ONCOLOGY, 13.
1163768-.
Schwartzberg, Lee S, Horinouchi, Hidehito, Chan, David, Chernilo, Sara, Tsai, Michaela L, Isla, Dolores, Escriu, Carles ORCID: 0000-0003-3638-3202, Bennett, John P, Clark-Langone, Kim, Svedman, Christer et al (show 1 more authors)
(2020)
Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance.
NPJ PRECISION ONCOLOGY, 4 (1).
15-.
Haragan, Alexander ORCID: 0000-0002-9747-563X
(2021)
PD-L1 expression and prediction of response to immune modulators in non-small cell lung cancer; reasons for its fragility and strategies to reduce it.
PhD thesis, University of Liverpool.
Haragan, Alexander ORCID: 0000-0002-9747-563X, Gosney, John, Field, John ORCID: 0000-0003-3951-6365, Davies, michael ORCID: 0000-0002-7609-4977, Escriu, Carles ORCID: 0000-0003-3638-3202 and Gruver, Aaron
(2019)
PD-L1 expression in resected non-small cell lung cancer: variation between primary tumour and nodal metastases.
.
Sallam, Mostafa, Wong, Helen and Escriu, Carles ORCID: 0000-0003-3638-3202
(2019)
Treatment beyond four cycles of first line Platinum and Etoposide chemotherapy in real-life patients with stage IV Small Cell Lung Cancer: a retrospective study of the Merseyside and Cheshire Cancer network.
BMC PULMONARY MEDICINE, 19 (1).
195-.